We are excited to share our latest research:
"Comparison Between Low Molecular Weight Heparin and Apixaban in the Prophylaxis Against Venous Thromboembolism After Laparoscopic Sleeve Gastrectomy"
🔍 Key Findings:
✔️ No venous thromboembolism (VTE) events occurred in either group.
✔️ Apixaban was found to be as effective and safe as low molecular weight heparin (LMWH) for post-bariatric surgery VTE prophylaxis.
✔️ Similar rates of postoperative bleeding (2%) in both groups.
✔️ The study highlights the potential advantages of DOACs in bariatric surgery, including ease of administration and non-requirement for monitoring.
💡 Why This Matters:
Venous thromboembolism is a serious postoperative risk in bariatric surgery, and anticoagulation strategies remain a critical area of research. Our randomized controlled trial (RCT) suggests that apixaban could be a viable alternative to LMWH, offering a simpler and potentially more patient-friendly approach to VTE prophylaxis.
📖 Read the full article here: DOI: 10.1007/s11695-025-07721-y
🔬 We welcome discussions, insights, and collaborations on the use of DOACs in bariatric surgery! Have you encountered similar findings in your practice? Let’s talk!
#BariatricSurgery #VTE #Anticoagulation #Apixaban #LMWH #ObesitySurgery #DOACs #PatientSafety #SurgicalResearch